Department Of Cardiology 3
101. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
102. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
103. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
104. Socioeconomic differences in food habits among 6- to 9-year-old children from 23 countries—WHO European Childhood Obesity Surveillance Initiative (COSI 2015/2017)
105. Baseline platelet count in percutaneous coronary intervention: a dose-response meta-analysis
106. Baseline platelet count in percutaneous coronary intervention: a dose-response meta-analysis
107. Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis
108. Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis
109. Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis
110. Phenotyping for percutaneous coronary intervention and long-term recurrent weighted outcomes
111. Phenotyping for percutaneous coronary intervention and long-term recurrent weighted outcomes
112. Prediction of clinical outcomes after percutaneous coronary intervention: Machine-learning analysis of the National Inpatient Sample
113. Prediction of clinical outcomes after percutaneous coronary intervention: Machine-learning analysis of the National Inpatient Sample
114. Prediction of clinical outcomes after percutaneous coronary intervention: Machine-learning analysis of the National Inpatient Sample
115. The Prognostic Utility of Mean Platelet Volume in Patients With Acute Coronary Syndrome: A Systematic Review With Meta-Analyses
116. The prognostic value of mean platelet volume in patients with coronary artery disease: An updated systematic review with meta-analyses
117. The prognostic value of mean platelet volume in patients with coronary artery disease: An updated systematic review with meta-analyses
118. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021
119. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021
120. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021
121. Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart
122. Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart
123. Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart
124. Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart
125. Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart
126. Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart
127. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
128. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
129. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
130. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
131. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
132. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology
133. Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
134. Trends and levels of the global, regional, and national burden of appendicitis between 1990 and 2021: findings from the Global Burden of Disease Study 2021
135. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
136. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
137. Urban and rural differences in frequency of fruit, vegetable, and soft drink consumption among 6–9-year-old children from 19 countries from the WHO European region
138. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
139. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
140. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
141. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
142. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
143. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
144. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
145. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
146. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
147. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
148. Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
149. Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
150. May Measurement Month 2022: an analysis of blood pressure screening results from Kazakhstan
1 2 3 4 5 9